UK’s Salient Bio launches robotic COVID-19 testing platformUK diagnostics firm Salient Bio has launched a robotics-driven COVID-19 mass testing platform after spinning out from Imperial Share XUK’s Salient Bio launches robotic COVID-19 testing platformhttps://pharmaphorum.com/news/uks-salient-launches-robotic-covid-19-testing-platform/
Brexit could hinder access to coronavirus vaccines, says pharma groupThe UK’s pharma industry trade body has warned that Brexit could derail the government’s efforts to get coronavirus Share XBrexit could hinder access to coronavirus vaccines, says pharma grouphttps://pharmaphorum.com/news/brexit-could-hinder-access-to-coronavirus-vaccines-says-pharma-group/
FDA approves Alnylam’s ultra-rare disease drug OxlumoThe FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), Share XFDA approves Alnylam’s ultra-rare disease drug Oxlumohttps://pharmaphorum.com/news/fda-approves-alynlams-ultra-rare-disease-drug-oxlumo/
Pfizer/BioNTech prep US COVID-19 vaccine launch after emergency filingPfizer and BioNTech have filed for emergency use of their COVID-19 vaccine candidate in the US, paving the Share XPfizer/BioNTech prep US COVID-19 vaccine launch after emergency filinghttps://pharmaphorum.com/news/pfizer-biontech-us-covid-19-vaccine-launch-emergency-filing/
Lilly’s baricitinib granted US emergency use in COVID-19Doctors in the US are to get another option to treat COVID-19 after the FDA granted an Emergency Share XLilly’s baricitinib granted US emergency use in COVID-19https://pharmaphorum.com/news/lillys-baricitinib-granted-us-emergency-use-in-covid-19/
NICE says yes to Braftovi combination for colorectal cancerTwo months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer (mCRC), NICE has Share XNICE says yes to Braftovi combination for colorectal cancerhttps://pharmaphorum.com/news/nice-says-yes-to-braftovi-combination-for-colorectal-cancer/
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarNovartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its Share XFDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarhttps://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/
NICE backs Lilly’s Emgality for migraine, adding pressure on NovartisUK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for Share XNICE backs Lilly’s Emgality for migraine, adding pressure on Novartishttps://pharmaphorum.com/news/nice-backs-lillys-emgality-for-migraine-adding-pressure-on-novartis-rival/
Pfizer begins US pilot delivery programme for COVID-19 vaccinePfizer has begun a pilot delivery programme in the US for its experimental COVID-19 vaccine, as the company Share XPfizer begins US pilot delivery programme for COVID-19 vaccinehttps://pharmaphorum.com/news/pfizer-begins-us-pilot-delivery-programme-for-covid-19-vaccine/
